Research

Research at Whitehead

Whitehead Institute provides researchers with the resources and freedom to follow their scientific instincts, form novel collaborations, and conduct high-risk research. While probing basic biological processes, the Institute’s 16 faculty Members and 2 Fellows develop innovative technologies and lay the foundation for projects that improve human health. They run pioneering programs in cancer, immunology, developmental biology, stem cell science, regenerative medicine, genetics, and genomics.

Members

 

Fellows

Research News

Schematic of how interrupting ATPIF1 rescues cells with mitochondrial dysfunction

March 27, 2014

Scientists find potential target for treating mitochondrial disorders

Mitochondria, long known as “cellular power plants” for their generation of the key energy source adenosine triphosphate (ATP), are essential for proper cellular functions. Mitochondrial defects are often observed in a variety of diseases, including cancer, Alzheimer’s disease, and Parkinson’s disease, and are the hallmarks of a number of untreatable genetic mitochondrial disorders whose manifestations range from muscle weakness to organ failure. Whitehead Institute scientists have identified a protein whose inhibition could hold the key to alleviating suffering caused by such disorders.

Whitehead Institute and Biogen Idec logos

March 25, 2014

Whitehead Institute and Biogen Idec Initiate Discovery Research Collaboration

Whitehead Institute today announced it has entered into a scientific research collaboration with Biogen Idec aimed at driving early stage research that may lead to the development of novel therapies across a broad range of disease areas.

Diagram of the Nutrostat machine

March 16, 2014

How diabetes drugs may work against cancer

Scientists at Whitehead Institute have pinpointed a major mitochondrial pathway that imbues cancer cells with the ability to survive in low-glucose environments. By identifying cancer cells with defects in this pathway or with impaired glucose utilization, the scientists can predict which tumors will be sensitive to these anti-diabetic drugs known to inhibit this pathway.

Graph of growth curves of wild type and amyloid-beta strains treated with clioquinol

March 3, 2014

Yeast model reveals Alzheimer’s drug candidate and its mechanism of action

Whitehead Institute scientists have used a yeast cell-based drug screen to identify a class of molecules that target the amyloid-β (Aβ) peptide involved in Alzheimer’s disease (AD).  

Recent papers

January 30, 2014

ZFHX4 interacts with the NuRD core member CHD4 and regulates the glioblastoma tumor-initiating cell state.

Cell Rep. 2014 Jan 30;6(2):313-24.


January 29, 2014

In vivo discovery of immunotherapy targets in the tumour microenvironment.

Nature. 2014 Jan 29.


January 29, 2014

Poly(A)-tail profiling reveals an embryonic switch in translational control.

Nature. 2014 Jan 29.


All research papers

© Whitehead Institute for Biomedical Research         Nine Cambridge Center    Cambridge, MA 02142